Agomelatine

Grey

Brand Name(s):Valdoxan

Indication:Depression (major)

Rationale:2

Considered:Feb-09

Review Date:Jan-20

Comments:
MHRA Drug Safety Update Nov 2014

Agomelatine (Valdoxan) may cause liver toxicity in some people. Test liver function before and during treatment. Do not start or continue treatment if serum transaminases exceed three times the upper limit of normal. Advise patients to stop taking agomelatine and to get medical help immediately if they have any signs or symptoms of liver injury.

http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON468288